Skip to content
AwardedSpainGoodsDynamic purchasing system€1,887,515

Adjudicación del Contrato Específico del Medicamento BIMEKIZUMAB, derivado del Sistema Dinámico de Adquisición del Suministro de Medicamentos Exclusivos, para el Consorci Sanitari Integral

Published
Published 5 June 2026

Overview

The Consorci Sanitari Integral has awarded a contract for the supply of the pharmaceutical medicine Bimekizumab, valued at €1,887,514.60, to UCB PHARMA, S.A. as of 29 May 2026. The procurement was conducted through a dynamic acquisition system for exclusive medicines and is now complete.

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€1,887,515
Procedure
Selective
Contract type
Dynamic purchasing system
Published
5 June 2026
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€1,887,515
Award date
29 May 2026
Contract period
29 May 2026 → 24 May 2027
Winner
  • UCB PHARMA, S.A.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    5 June 2026

Contracting authority

  • Consorci Sanitari Integral

    Procuring entity

    L’Hospitalet de Llobregat, Spain

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Adjudicación del Contrato Específico del Medicamento BIMEKIZUMAB, derivado del Sistema Dinámico de Adquisición del Suministro de Medicamentos Exclusivos, para el Consorci Sanitari Integral — won by UCB PHARMA, S.A. — Skim